13-Valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants

Pediatrics

Volumn 135, Issue 4, 2015, Pages e876-e886

  Martinón Torres, Federico ^a   Czajka, Hanna ^b   Center, Kimberly J ^c   Wysocki, Jacek ^d   Majda Stanislawska, Ewa ^e   Omeñaca, Felix ^f   Iturbe, Enrique Bernaola ^g   Gamero, Daniel Blazquez ^h   Concheiro Guisán, Ana ⁱ   Gimenez Sanchez, Francisco ^j   Szenborn, Leszek ^k   Giardina, Peter C ^c   Patterson, Scott ^c   Gruber, William C ^c   Scott, Daniel A ^c   Gurtman, Alejandra ^c  

^a Instituto de Salud Carlos III   (Spain)

^b Wojewodzki Spec Szpital Dzieciecy   (Poland)

^c PFIZER INC   (United States)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f HOSPITAL INFANTIL LA PAZ   (Spain)

^g Universidad Pública de Navarra   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^j HOSPITAL TORRECÁRDENAS   (Spain)

^k WROCLAW MEDICAL UNIVERSITY   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE CONVULSION; FEMALE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GESTATIONAL AGE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; IRRITABILITY; MALE; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEROTYPE; SKIN DISEASE; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; IMMUNOLOGY; INFANT, PREMATURE, DISEASES; INTRAMUSCULAR DRUG ADMINISTRATION; NEWBORN; POLAND; SPAIN; STREPTOCOCCUS PNEUMONIAE;

ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INJECTIONS, INTRAMUSCULAR; MALE; PNEUMOCOCCAL VACCINES; POLAND; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 84927734879     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2941     Document Type: Article

References (28)

1. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122-140
2. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21(3):182-186
3. Okoko BJ, Wesumperuma LH, Hart AC. Materno-foetal transfer of H. influenzae and pneumococcal antibodies is influenced by prematurity and low birth weight: implications for conjugate vaccine trials. Vaccine. 2001;20(5-6):647-650
4. Omeñaca F, Garcia-Sicilia J, Boceta R, Sistiaga-Hernando A, García-Corbeira P. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J. 2007;26(9):824-829
5. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine. 2005;23(14):1703-1708
6. Moss SJ, Fenton AC, Toomey JA, Grainger AJ, Smith J, Gennery AR. Responses to a conjugate pneumococcal vaccine in preterm infants immunized at 2, 3, and 4 months of age. Clin Vaccine Immunol. 2010;17(11):1810-1816
7. Ruggeberg JU, Collins C, Clarke P, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine. 2007;25(2):264-271
8. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Available at: ftp://ftp.cordis.europa.eu/pub/fp7/docs/ethical-considerations-paediatrics-en.pdf. Accessed April 2, 2014
9. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10(4):514-519
10. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29(41):7207-7211
11. World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. WHO Technical Report Series 2009; Annex 2: No. 927. Available at: www.who.int/biologicals/areas/vaccines/pneumo/Pneumo-final-23APRIL-2010.pdf. Accessed August 4, 2014
12. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25(19):3816-3826
13. Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, et al; 3007 Study Group. 13-Valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J. 2012;31(4):392-399
14. Chan IS, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics. 1999;55(4):1202-1209
15. Melville JM, Moss TJ. The immune consequences of preterm birth. Front Neurosci. 2013;7:79
16. Berrington JE, Cant AJ, Matthews JN, O'Keeffe M, Spickett GP, Fenton AC. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics. 2006;117 (4). Available at: www.pediatrics.org/cgi/content/full/117/4/e717
17. Collins CL, Ruggeberg JU, Balfour G, et al. Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants. Pediatr Infect Dis J. 2005;24(11):966-968
18. Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and Wales. Clin Infect Dis. 2013;56(5):633-640
19. Kieninger DM, Kueper K, Steul K, et al; 006 Study Group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28(25):4192-4203
20. Yeh SH, Gurtman A, Hurley DC, et al; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126 (3). Available at: www.pediatrics.org/cgi/content/full/126/3/e493
21. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232-6238
22. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-9131
23. Rückinger S, Van Der Linden M, Von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect Dis. 2010;10:12
24. Guarino A, Albano F, Ashkenazi S, et al; European Society for Paediatric Gastroenterology, Hepatology, and Nutrition; European Society for Paediatric Infectious Diseases. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. 2008;46(suppl 2):S81-S122
25. Ogilvie I, Khoury H, Goetghebeur MM, El Khoury AC, Giaquinto C. Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis. 2012;12:62
26. Boloursaz MR, Lotfian F, Aghahosseini F, et al. Epidemiology of lower respiratory tract infections in children. J Compr Pediatr. 2013;4(2):93-98
27. Zimmerman RK, Middleton DB. Vaccines for persons at high risk, 2007. J Fam Pract. 2007;56(2 suppl Vaccines):S38-S46, C34-C35
28. Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics. 2011;127 (6). Available at: www.pediatrics.org/cgi/content/full/127/6/e1375